[Articles] Vulvar field resection based on ontogenetic cancer field theory for surgical treatment of vulvar carcinoma: a single-centre, single-group, prospective trial
Our results support the theory of ontogenetic cancer fields for vulvar carcinoma, accord with our previous findings in cervical cancer, and suggest the general applicability of the theory. Application of the concept of cancer field resection could improve outcomes in patients with vulvar carcinoma, but needs to be investigated further in multicentre randomised controlled trials. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 9, 2018 Category: Cancer & Oncology Authors: Michael H öckel, Sophia Trott, Nadja Dornhöfer, Lars-Christian Horn, Bettina Hentschel, Benjamin Wolf Tags: Articles Source Type: research
[Articles] Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
The safety profile of the combination avelumab plus axitinib in treatment-naive patients with advanced renal-cell carcinoma seemed to be manageable and consistent with that of each drug alone, and the preliminary data on antitumour activity are encouraging. A phase 3 trial is assessing avelumab and axitinib compared with sunitinib monotherapy. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 9, 2018 Category: Cancer & Oncology Authors: Toni K Choueiri, James Larkin, Mototsugu Oya, Fiona Thistlethwaite, Marcella Martignoni, Paul Nathan, Thomas Powles, David McDermott, Paul B Robbins, David D Chism, Daniel Cho, Michael B Atkins, Michael S Gordon, Sumati Gupta, Hirotsugu Uemura, Yoshihiko Tags: Articles Source Type: research
[Comment] Vulvar field resection: innovative procedure or same old?
In The Lancet Oncology, Michael H öckel and colleagues1 report the results of a single-centre prospective study of surgical resection of vulvar cancer based on ontogenetic cancer fields. Patients were treated with vulvar field resection, therapeutic lymph node dissection, and anatomical reconstruction without adjuvant radiotherapy, and recurrence-free and disease-specific survival results were encouraging. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 9, 2018 Category: Cancer & Oncology Authors: Tiffany Zigras, Allan Covens Tags: Comment Source Type: research
[Comment] Aiming for complete responses in renal-cell carcinoma
Treatments for metastatic renal-cell carcinoma have evolved rapidly in the past decade, and since 2006, targeted therapies have been the cornerstone of treatments, with pazopanib or sunitinib leading to objective responses in 24 –31% of patients.1 Deep tumour responses have been described as a surrogate measure for overall survival in patients with renal-cell carcinoma.2 However, because these are rarely achieved with current standard first-line targeted therapies, novel tyrosine-kinase inhibitors (TKIs) are being tested. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 9, 2018 Category: Cancer & Oncology Authors: Viktor Gr ünwald Tags: Comment Source Type: research
[News] Colorectal adenoma risk in childhood cancer survivors
Survivors of childhood cancer treated with abdominopelvic radiotherapy, total body irradiation, or cisplatin have an increased risk of developing colorectal adenomas and carcinomas, according to a retrospective cohort study. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 8, 2018 Category: Cancer & Oncology Authors: Talha Khan Burki Tags: News Source Type: research
[News] Dasatinib in paediatric chronic myeloid leukaemias
Treatment with the tyrosine kinase inhibitor (TKI) dasatinib achieved clinically important responses in paediatric patients with chronic myeloid leukaemia (CML) in a phase 2, non-randomised trial. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 8, 2018 Category: Cancer & Oncology Authors: Priya Venkatesan Tags: News Source Type: research
[News] Larotrectinib in TRK fusion-positive cancers
The TRK inhibitor larotrectinib is associated with a high proportion of patients achieving an overall response with TRK fusion-positive cancers, according to a new combined analysis of three trials. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Talha Khan Burki Tags: News Source Type: research
[Clinical Picture] Large parapharyngeal mass: a challenging differential diagnosis
A 35-year-old male patient presented at the Otolaryngology Department of the Policlinico Umberto I, Sapienza University of Rome (Rome, Italy) in February, 2017 with a 14-month history of breathing difficulties and dysphagia. Endoscopic examination showed a bulking in the right parapharyngeal space, extending into the oropharynx, dislocating the pharyngeal wall and causing a noticeable obstruction of respiratory tract; no externally visible cervical mass was present. Laboratory investigations and radiography of the chest were normal. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Massimo Ralli, Marco de Vincentiis, Antonio Greco Tags: Clinical Picture Source Type: research
[Policy Review] Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative
The Response Assessment in Neuro-Oncology-Patient-Reported Outcome (RANO-PRO) working group is an international multidisciplinary collaboration that provides guidance on the use of patient-reported outcome (PRO) measures in clinical trials and practice for adult patients with brain tumours. Findings from both PROs and traditional outcome measures, such as survival, and clinical or radiological response, are essential to inform the research community, policy makers, physicians, and patients in the treatment decision-making process. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Linda Dirven, Terri S Armstrong, Jaishri O Blakeley, Paul D Brown, Robin Grant, Rakesh Jalali, Heather Leeper, Tito Mendoza, Lakshmi Nayak, Jaap C Reijneveld, Emilie Le Rhun, Tobias Walbert, Michael Weller, Patrick Y Wen, Martin J B Taphoorn Tags: Policy Review Source Type: research
[Review] Novel therapies for malignant pleural mesothelioma
Malignant pleural mesothelioma is a rare cancer that is typically associated with exposure to asbestos. Patients with malignant pleural mesothelioma have poor outcomes with suboptimal therapeutic options and currently no treatment is curative. The standard frontline treatment, cisplatin plus pemetrexed chemotherapy, has only short and insufficient efficacy, and no validated treatment beyond first-line therapy is available. New therapeutic strategies are therefore needed. The addition of bevacizumab (an anti-VEGF antibody) combined with cisplatin plus pemetrexed has shown some promise. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Arnaud Scherpereel, Frederic Wallyn, Steven M Albelda, Camille Munck Tags: Review Source Type: research
[Review] Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease
Variations in the reporting of potentially confounding variables in studies investigating systemic treatments for unresectable pancreatic cancer pose challenges in drawing accurate comparisons between findings. In this Review, we establish the first international consensus on mandatory baseline and prognostic characteristics in future trials for the treatment of unresectable pancreatic cancer. We did a systematic literature search to find phase 3 trials investigating first-line systemic treatment for locally advanced or metastatic pancreatic cancer to identify baseline characteristics and prognostic variables. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Emil ter Veer, L Bengt van Rijssen, Marc G Besselink, Rosa M A Mali, Jordan D Berlin, Stefan Boeck, Franck Bonnetain, Ian Chau, Thierry Conroy, Eric Van Cutsem, Gael Deplanque, Helmut Friess, Bengt Glimelius, David Goldstein, Richard Herrmann, Roberto Lab Tags: Review Source Type: research
[Perspectives] The evolution of anticancer drug discovery from plants
Compared with human beings, plants are arguably superior synthetic chemists. Plants have evolved to produce an extremely diverse range of chemical compounds, often with steric complexity, as a strategy to survive and protect against challenges in their environments. For example, many plant alkaloid chemicals are associated with toxic effects, considered an evolutionary strategy to deter predators. It is therefore not surprising that many plant chemicals have potent activities that target human diseases, including cancer. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Melanie-Jayne R Howes Tags: Perspectives Source Type: research
[Perspectives] Cancer control in war-torn Iraq
Before 1980, the Iraqi health system was described by the UN as the best health-care system in the Middle East with respect to its infrastructure, medical expertise and universal health coverage through its free of charge services. The repercussions of the war against Iran (1980 –88), followed by the Gulf wars (1990–91 and 2003–11), and the civil war initiated by the Islamic State of Iraq and the Levant (2014–17), resulted in a severe decline in the availability of medical resources, funds, and medical personnel; factors that were exacerbated by an excess of bureauc racy, corruption, and turmoil at a time when the ...
Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Authors: Nada Alwan, David Kerr Tags: Perspectives Source Type: research
[Corrections] Correction to Lancet Oncol 2018; 19: 257 –66
O'Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1 –2 trial. Lancet Oncol 2018; 19: 257–66—The name of the last author of this Article should have been John Kuruvilla. This correction has been made to the online version as of Feb 28, 2018. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Tags: Corrections Source Type: research
[Corrections] Correction to Lancet Oncol 2018; 19: 87 –100
Di Leo A, Johnston S, Lee KS, et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018; 19: 87 –100—In table 1, the proportion of Asian patients in the buparlisib plus fulvestrant group (second column) should be 7%. In figure 3, the total number of Asian patients should be 29. In the Results section, the following sentence should have read “In the 11 (13%) cases of discordance, a PIK3CA wild-type tumour sample and PI...
Source: The Lancet Oncology - March 1, 2018 Category: Cancer & Oncology Tags: Corrections Source Type: research
